PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 89 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2022. The put-call ratio across all filers is 1.18 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $11,124 | +11.2% | 3,600 | -19.8% | 0.00% | 0.0% |
| Q3 2022 | $10,000 | +42.9% | 4,489 | +68.2% | 0.00% | 0.0% |
| Q2 2022 | $7,000 | -61.1% | 2,669 | -57.4% | 0.00% | -50.0% |
| Q1 2022 | $18,000 | -58.1% | 6,269 | -56.7% | 0.00% | -33.3% |
| Q4 2021 | $43,000 | +65.4% | 14,469 | +441.9% | 0.00% | 0.0% |
| Q3 2020 | $26,000 | +2500.0% | 2,670 | +2125.0% | 0.00% | – |
| Q2 2020 | $1,000 | -98.6% | 120 | -97.9% | 0.00% | -100.0% |
| Q2 2019 | $71,000 | +163.0% | 5,600 | +648.7% | 0.01% | +133.3% |
| Q1 2017 | $27,000 | -90.9% | 748 | -83.1% | 0.00% | -90.9% |
| Q3 2016 | $296,000 | +61.7% | 4,424 | -28.3% | 0.03% | +73.7% |
| Q2 2016 | $183,000 | +96.8% | 6,167 | +670.9% | 0.02% | +11.8% |
| Q2 2015 | $93,000 | +365.0% | 800 | +300.0% | 0.02% | +240.0% |
| Q1 2014 | $20,000 | -35.5% | 200 | -33.3% | 0.01% | -66.7% |
| Q4 2013 | $31,000 | – | 300 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 2,536,156 | $21,405,000 | 2.24% |
| Palo Alto Investors LP | 1,396,163 | $11,784,000 | 0.99% |
| Camber Capital Management LP | 1,950,000 | $16,458,000 | 0.98% |
| TANG CAPITAL MANAGEMENT LLC | 800,000 | $6,752,000 | 0.95% |
| Capital Impact Advisors, LLC | 147,303 | $1,243,000 | 0.52% |
| Sofinnova Investments, Inc. | 638,026 | $5,385,000 | 0.50% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 963,212 | $8,130,000 | 0.26% |
| RICE HALL JAMES & ASSOCIATES, LLC | 466,482 | $3,937,000 | 0.22% |
| PDT Partners, LLC | 204,238 | $1,724,000 | 0.14% |
| Eversept Partners, LP | 58,251 | $491,638 | 0.12% |